CytomX Therapeutics (CTMX)
(Delayed Data from NSDQ)
$1.63 USD
-0.05 (-2.98%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $1.63 0.00 (0.00%) 7:54 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Brokerage Reports
CytomX Therapeutics, Inc. [CTMX]
Reports for Purchase
Showing records 21 - 40 ( 149 total )
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Probing into 2023; New CX-2029 Data, Moderna Collaboration
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Moderna Alliance Highlights Importance of Masking Technology; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Regeneron Partnership Enables Further Bi-Specific Development; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Financials; Clinical Data Catalysts Approaching; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Solid Preclinical EpCAM ADC Data at World ADC Conference; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial BMS-986249 Phase 1 Data Looks Decent; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Clinical Focus on Partner Programs Following Restructuring
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Financials; Clinical Data Catalysts in Late 2022; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Restructuring to Extend Cash Runway into 2025; Two INDs for 2H:23
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Restructuring Extends Operational Runway Into 2025; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Disappointing Phase 2 Data; Higher Dosing Halted; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL and Reducing PT to $2; Pral Rav Hits and Misses
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R